Clinical Trials at UI Healthcare Mission Cancer and Blood - Fort Dodge
As of August 2026, 29 paid clinical trials are recruiting at UI Healthcare Mission Cancer and Blood - Fort Dodge in Fort Dodge, Iowa. Active studies at this site cover conditions such as Anatomic Stage II Breast Cancer AJCC v8, Lung Non-Small Cell Carcinoma and Anatomic Stage IIIA Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
29 clinical trials at UI Healthcare Mission Cancer and Blood - Fort Dodge
·Clear filters·Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Common conditions studied in Fort Dodge
- Anatomic Stage II Breast Cancer AJCC v8 (5 active studies)
- Lung Non-Small Cell Carcinoma (4 active studies)
- Anatomic Stage IIIA Breast Cancer AJCC v8 (3 active studies)
- Chronic Lymphocytic Leukemia (3 active studies)
- Malignant Solid Neoplasm (3 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
Leading research sponsors in Fort Dodge
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- NRG Oncology
- ECOG-ACRIN Cancer Research Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Fort Dodge?
There are approximately 61 recruiting clinical trials in Fort Dodge, Iowa listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Fort Dodge pay participants?
Most recruiting trials in Fort Dodge compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Fort Dodge?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Fort Dodge?
The most common conditions under active study in Fort Dodge include Anatomic Stage II Breast Cancer AJCC v8 (5), Lung Non-Small Cell Carcinoma (4), Anatomic Stage IIIA Breast Cancer AJCC v8 (3), Chronic Lymphocytic Leukemia (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Fort Dodge?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Fort Dodge on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Fort Dodge?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Fort Dodge?
Recruiting research sites in Fort Dodge include McFarland Clinic - Trinity Cancer Center, UI Healthcare Mission Cancer and Blood - Fort Dodge, Trinity Regional Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Fort Dodge right now?
The largest active categories in Fort Dodge are Cancer & tumors (56), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.